Prime Research

Latest Research

Keytruda continues to stack up FDA approvals for more cancer indications

Since its first FDA approval in 2014, Merck’s Keytruda® (pembrolizumab) has been delivering results for treating a wide range of cancers. It received FDA approvals…

Read More

Biosimilar strategy for infliximab by MedDrive™ includes the reference drug

The U.S. Food and Drug Administration (FDA) first approved Janssen Biotech’s Remicade® (infliximab) in April of 1998 for the treatment of Crohn’s disease. It was…

Read More

February 2022 decisions expected from the FDA

At Prime Therapeutics (Prime), we’ve positioned ourselves to best prepare our clients to manage new drugs. Our clinical and trade relations teams keep a keen…

Read More
Select a Research Type
Drug pipeline updates
Prime analysis
Scientific presentations
Loading …